索雷尔证券集团指出，“该公司在高端市场和产品的业务调整能否在9到12个月内产生效果，我们对此表示怀疑。

The firm notes, "We're skeptical that a business realignment to high-end markets/products can be impactful over the immediate 6-12 months."

youdao

索雷尔证券集团(Soleil Securities Group)把迈瑞医疗公司评级从买入下调到持有，把目标股价从44美元降低到27美元，表示该公司未来前景尚不明朗。

Soleil Securities downgrades Mindray Medical (NYSE: MR) from Buy to Hold and lowers the price target from $44 to $27. The firm cites a "hazy" outlook for the future.

youdao